Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

SAN FRANCISCO, July 10, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin’s exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of PepGen Inc. (NASDAQ: PEPG)?Did you purchase your shares between March 7, 2024 and March 3, 2025, inclusive?Did you lose money in your invest ...

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Group 1: Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Group 2: Financial Disclosures and Stock Impact - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [5]. - Following the October announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Group 1 - A complaint has been filed against Vestis Corporation in the United States District Court for the Southern District of New York, alleging violations of the Securities Exchange Act of 1934 [1] - The complaint involves investors who purchased or acquired Vestis securities between May 2, 2024, and May 6, 2025, claiming misrepresentations regarding the company's growth potential [1][3] - Bernstein Liebhard LLP, the law firm representing the investors, has a history of recovering over $3.5 billion for clients and has been recognized for its success in class action litigations [5] Group 2 - Investors interested in participating in the class action must file papers by August 8, 2025, to serve as lead plaintiff, although participation in recovery does not require this role [4] - The representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4]

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for alleged violations of the Securities Exchange Act of 1934, specifically regarding misrepresentations about the company's EBITDA targets for 2025 [1][2]. Group 1: Lawsuit Details - The complaint was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025 [1]. - The lawsuit alleges that the company and certain senior officers made misrepresentations concerning the company's financial targets [2]. Group 2: Legal Participation - Investors who wish to serve as lead plaintiffs must file necessary documents by August 1, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [3]. - All legal representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against MicroStrategy Incorporated, alleging violations of the Securities Exchange Act of 1934 due to misrepresentations about the company's bitcoin-focused investment strategy and treasury operations [1][3]. Group 1: Lawsuit Details - The complaint was filed in the United States District Court for the Eastern District of Virginia on behalf of investors who acquired MicroStrategy securities between April 30, 2024, and April 4, 2025 [1]. - The lawsuit claims that the defendants, including certain senior officers of the company, made false statements regarding the anticipated profitability of the company's investment strategy [3]. Group 2: Legal Participation - Investors who purchased or acquired MicroStrategy securities are encouraged to discuss their legal rights and options, with a deadline to file as lead plaintiff by July 15, 2025 [4]. - Participation in the lawsuit does not require serving as lead plaintiff, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Firm Background - Bernstein Liebhard LLP, the law firm representing the investors, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A class action lawsuit has been filed against Open Lending Corporation and certain senior officers for alleged violations of the Securities Exchange Act of 1934, specifically regarding misrepresentations about the company's risk-based pricing models [1][2]. Group 1: Legal Action Details - The complaint was filed in the United States District Court for the Western District of Texas on behalf of investors who purchased Open Lending securities between February 24, 2022, and March 31, 2025 [1]. - Investors are encouraged to join the class action lawsuit and can contact the Investor Relations Manager for more information [2][3]. Group 2: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].